Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions.
作者信息
Maiti Abhishek, Daver Naval G
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
J Clin Oncol. 2022 Dec 1;40(34):3994-3997. doi: 10.1200/JCO.22.01505. Epub 2022 Sep 7.
Abstract
摘要
相似文献
1
Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions.移植后环境中的依普奈妥单抗：作用机制与未来方向
J Clin Oncol. 2022 Dec 1;40(34):3994-3997. doi: 10.1200/JCO.22.01505. Epub 2022 Sep 7.
2
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.Eprenetapopt 联合阿扎胞苷用于异基因造血干细胞移植后 -突变急性髓系白血病和骨髓增生异常综合征。
J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11.
3
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.Eprenetapopt联合维奈克拉和阿扎胞苷治疗TP53突变的急性髓系白血病：一项1期剂量探索与扩展研究
Lancet Haematol. 2023 Apr;10(4):e272-e283. doi: 10.1016/S2352-3026(22)00403-3.
4
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.eprenetapopt（APR-246）联合 pembrolizumab 治疗晚期或转移性实体瘤的 Ib 期研究。
ESMO Open. 2022 Oct;7(5):100573. doi: 10.1016/j.esmoop.2022.100573. Epub 2022 Sep 7.
5
Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes.Eprenetapopt（APR-246）联合阿扎胞苷治疗 -突变骨髓增生异常综合征。
J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15.
6
Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction.依普那妥触发铁死亡，抑制NFS1半胱氨酸脱硫酶，并与丝氨酸和甘氨酸饮食限制协同作用。
Sci Adv. 2022 Sep 16;8(37):eabm9427. doi: 10.1126/sciadv.abm9427. Epub 2022 Sep 14.
7
Life after transplant: are we becoming high maintenance in AML?移植后的生活：在急性髓系白血病中我们是否变得难以维持？
Bone Marrow Transplant. 2016 Nov;51(11):1423-1430. doi: 10.1038/bmt.2016.160. Epub 2016 Jun 20.
8
Carcinogenicity of alkylating cytostatic drugs: conclusions and directions for future research.烷化剂类细胞毒性药物的致癌性：结论与未来研究方向
IARC Sci Publ. 1986(78):321-3.
9
The chemoprevention of cancer: directions for the future.癌症的化学预防：未来的方向
Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):509-12.
10
Future directions and strategies.未来的方向与策略。
Lung Cancer. 1995 Apr;12 Suppl 1:S199-201. doi: 10.1016/0169-5002(95)00437-6.
引用本文的文献
1
Ferroptosis-Resistant Adipocytes Drive Keloid Pathogenesis via GPX4-Mediated Adipocyte-Mesenchymal Transition and Iron-Cystine Metabolic Communication.抗铁死亡脂肪细胞通过GPX4介导的脂肪细胞-间充质转化和铁-胱氨酸代谢通讯驱动瘢痕疙瘩发病机制。
Int J Biol Sci. 2025 Jul 28;21(11):5097-5115. doi: 10.7150/ijbs.114930. eCollection 2025.
2
Pharmacological reactivation of p53 in the era of precision anticancer medicine.精准抗癌医学时代的 p53 药理学再激活。
Nat Rev Clin Oncol. 2024 Feb;21(2):106-120. doi: 10.1038/s41571-023-00842-2. Epub 2023 Dec 15.
3
TAM family kinases as therapeutic targets at the interface of cancer and immunity.酪氨酸激酶家族作为癌症与免疫交叉领域的治疗靶点。
Nat Rev Clin Oncol. 2023 Nov;20(11):755-779. doi: 10.1038/s41571-023-00813-7. Epub 2023 Sep 4.
本文引用的文献
1
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.伴有或不伴有 TP53 突变的不良细胞遗传学患者接受 Venetoclax 和阿扎胞苷治疗的结局。
Clin Cancer Res. 2022 Dec 15;28(24):5272-5279. doi: 10.1158/1078-0432.CCR-22-1183.
2
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.Eprenetapopt 联合阿扎胞苷用于异基因造血干细胞移植后 -突变急性髓系白血病和骨髓增生异常综合征。
J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11.
3
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.TP53 突变型急性髓系白血病采用不断发展的一线治疗方案的结果：异基因干细胞移植对生存的影响。
Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30.
4
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.地西他滨联合维奈克拉治疗 TP53 突变急性髓系白血病的疗效。
Cancer. 2021 Oct 15;127(20):3772-3781. doi: 10.1002/cncr.33689. Epub 2021 Jul 13.
5
Eprenetapopt Plus Azacitidine in -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).Eprenetapopt 联合阿扎胞苷治疗 - 突变型骨髓增生异常综合征和急性髓系白血病：一项由法国骨髓增生异常综合征研究组（GFM）开展的 II 期研究。
J Clin Oncol. 2021 May 10;39(14):1575-1583. doi: 10.1200/JCO.20.02342. Epub 2021 Feb 18.
6
Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes.Eprenetapopt（APR-246）联合阿扎胞苷治疗 -突变骨髓增生异常综合征。
J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15.
7
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia.APR-246 通过铁死亡诱导急性髓系白血病早期细胞死亡。
Haematologica. 2022 Feb 1;107(2):403-416. doi: 10.3324/haematol.2020.259531.
8
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病中突变 TP53 变异等位基因频率的预后和治疗影响。
Blood Adv. 2020 Nov 24;4(22):5681-5689. doi: 10.1182/bloodadvances.2020003120.
9
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).异基因造血干细胞移植治疗伴有内部串联重复突变的急性髓系白血病后的索拉非尼维持治疗（SORMAIN）。
J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16.
10
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.基因组背景和TP53等位基因频率决定了TP53突变型骨髓增生异常综合征的临床结局。
Blood Adv. 2020 Feb 11;4(3):482-495. doi: 10.1182/bloodadvances.2019001101.
Zotero 插件